Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial of its 21-valent pneumococcal conjugate vaccine, V116, confirming earlier topline results. The data, released this week, highlights the vaccine’s immunogenicity, tolerability, and safety in comparison to Pfizer’s (NYSE: PFE) 20-valent Prevnar 20/Apexxnar in unvaccinated adults.
The findings indicate that 30 days post-vaccination, V116 demonstrated comparable or superior immunogenicity across most serotypes when compared to Prevnar 20/Apexxnar, while maintaining a similar safety profile. V116 is designed to protect against serotypes responsible for approximately 83% of pneumococcal disease in the elderly population within the United States, positioning it as a potential first-of-its-kind pneumococcal conjugate vaccine specifically tailored for adults.- Flcube.com
